PACB — PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

—
Nasdaq · Unknown · Unknown · CIK 1299130 ·
Last close
$1.82
Market Cap
$565.71M
52W High
$3.44
52W Low
$1.07
ADV30
13,023,521
Next earnings
2026-11-04

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 40,564,000 13,470,000 -37,002,000 -37,846,000 721,096,000 55,907,000 782,476,000
Jun 2026 39,007,000 12,638,000 -44,610,000 -44,741,000 751,850,000 61,003,000 785,063,000
Mar 2026 37,178,000 12,841,000 -54,153,000 -8,275,000 782,365,000 56,274,000 779,999,000
Dec 2025 44,645,000 16,566,000 -41,197,000 -40,371,000 784,083,000 63,707,000 778,734,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-118,050,000
Investing CF
$120,861,000
Financing CF
$3,161,000
CapEx
$-13,065,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.43
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-2,748,318,000
Inventory
$61,084,000
Receivables
$31,104,000
ST Investments
$175,870,000
EBIT TTM
$-123,231,000
Pretax Income TTM
$-130,560,000
Interest Exp TTM
$7,329,000
Analysts
7

Yahoo Snapshot (yfinance, live)

Total Revenue
$161,394,000
EBITDA
$-153,032,992
Free Cash Flow
$291,644,736
Enterprise Value
$1,207,812,992
Total Cash
$199,418,000
Total Debt
$705,369,024
Shares Out
310,830,759
Trailing EPS
$-0.42
Book Value
$-0.20
ROE
-929.3%
ROA
-43.5%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 160,005,000 -557,561,000 -546,376,000 784,083,000 778,734,000 5,349,000 -111,209,000
Dec 2024 154,014,000 -290,663,000 -309,851,000 1,260,447,000 753,853,000 506,594,000 -206,058,000
Dec 2023 200,521,000 -310,365,000 -306,735,000 1,746,013,000 1,044,709,000 701,304,000 -259,173,000
Dec 2022 128,304,000 -304,819,000 -314,248,000 1,767,086,000 1,204,182,000 562,904,000 -263,211,000

TTM Snapshot

Revenues TTM
$159,271,000
NetIncome TTM
$-131,387,000
OpCashFlow TTM
—
Assets (Latest)
$751,850,000
Forward EPS
$-0.42

Max Pain — expiry 2026-12-18

max pain strike: $2.00 · spot: $1.83 · call oi: 129,619 · put oi: 4,740
Expected Move to 2026-12-18: ±$0.38 (20.49%) — implied range $1.46 – $2.21 · ATM straddle on $2.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
NCDL Nuveen Churchill Direct Lending Corp. $563.77M $11.48 —
SENS Senseonics Holdings, Inc. $556.57M $10.16 —
SBOEF SBO AG/ADR $555.52M $35.25 —
YSS York Space Systems Inc. $576.17M $4.25 —
VMO Invesco Municipal Opportunity Trust $577.29M $8.56 —

News headlines (Yahoo Finance, 1h cache)

PacBio to Participate in the Piper Sandler 38th Annual Healthcare Conference
2026-11-17 21:05 · Yahoo
Here's Why Pacific Biosciences (PACB) Is a Great 'Buy the Bottom' Stock Now
2026-11-16 13:55 · Yahoo
PacBio (PACB) Stock Sees Split Analyst Revisions As Fair Value Edges Higher
2026-11-16 05:14 · Yahoo
Pacific Biosciences of California Inc (PACB) (Q3 2026) Earnings Call Highlights: Revenue Grows ...
2026-11-05 21:08 · Yahoo
Pacific Biosciences of California (PACB) Reports Q3 Loss, Beats Revenue Estimates
2026-11-04 23:45 · Yahoo
What Pacific Biosciences of California (PACB) Said on Its Q3 Earnings Call
2026-11-04 23:14 · Yahoo
Pacific Biosciences: Q3 Earnings Snapshot
2026-11-04 22:24 · Yahoo
PacBio (NASDAQ:PACB) reports bullish Q3 2026
2026-11-04 21:45 · Yahoo
PacBio Announces Third Quarter 2026 Financial Results
2026-11-04 21:05 · Yahoo
Pacific Biosciences of California (PACB) Rises As Market Takes a Dip: Key Facts
2026-10-29 21:15 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.